Overview

Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

Status:
Recruiting
Trial end date:
2025-05-30
Target enrollment:
Participant gender:
Summary
This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a cardiovascular event.
Phase:
Phase 3
Details
Lead Sponsor:
Amgen
Treatments:
Antibodies, Monoclonal
Evolocumab